Covid-19 Research

Research Article

CA19-9 as a Diagnostic Biomarker for Pancreatic Cancer

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Research Article
Subject Medicine Group
OCLC JBRES Record
Nandi Shalita*
Issue: Volume5-Issue10
Pages: 1349-1354
Received: 2024-10-10
Accepted: 2024-10-18
Published: 2024-10-25

Abstract

CA19-9 is a biomarker often used in pancreatic cancer diagnosis; it measures serum CA19-9 levels in the blood which corresponds to cancer status and even staging. It is used clinically but not as a screening biomarker as it doesn’t have the specificity needed to make it cost-effective in a screening programme. It can be used before and after treatment as it can help in choosing a treatment plan. It is used to see if this treatment is working, so it works as a predictive and prognostic biomarker as well. It’s recently been used alongside tumour marker genes to improve its sensitivity and specificity.

FullText HTML FullText PDF DOI: 10.37871/jbres2022 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2024 Shalita N. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Shalita N. CA19-9 as a Diagnostic Biomarker for Pancreatic Cancer. J Biomed Res Environ Sci. 2024 Oct 25; 5(10): 1349-1354. doi: 10.37871/jbres2022, Article ID: JBRES2022, Available at: https://www.jelsciences.com/articles/jbres2022.pdf

Subject area(s)

OncologyCancer

References

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12. PMID: 35020204.
  2. Long J, Luo GP, Xiao ZW, Liu ZQ, Guo M, Liu L, Liu C, Xu J, Gao YT, Zheng Y, Wu C, Ni QX, Li M, Yu X. Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. Cancer Lett. 2014 May 1;346(2):273-7. doi: 10.1016/j.canlet.2014.01.004. Epub 2014 Jan 21. PMID: 24462819.
  3. Petersen GM. Familial pancreatic cancer. Semin Oncol. 2016 Oct;43(5):548-553. doi: 10.1053/j.seminoncol.2016.09.002. Epub 2016 Sep 22. PMID: 27899186; PMCID: PMC5234085.
  4. Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, Griffin C, Cameron JL, Yeo CJ, Kern S, Hruban RH. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004 Apr 1;64(7):2634-8. doi: 10.1158/0008-5472.can-03-3823. PMID: 15059921.
  5. Egawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, Hatori T, Maguchi H, Yanagisawa A, Tanaka M. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas. 2012 Oct;41(7):985-92. doi: 10.1097/MPA.0b013e318258055c. PMID: 22750974.
  6. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979 Nov;5(6):957-71. doi: 10.1007/BF01542654. PMID: 94699.
  7. MKudelka MR, Ju T, Heimburg-Molinaro J, Cummings RD. Simple sugars to complex disease--mucin-type O-glycans in cancer. Adv Cancer Res. 2015;126:53-135. doi: 10.1016/bs.acr.2014.11.002. Epub 2015 Feb 7. PMID: 25727146; PMCID: PMC5812724.
  8. Goldsmith SJ. Radioimmunoassay: review of basic principles. Semin Nucl Med. 1975 Apr;5(2):125-52. doi: 10.1016/s0001-2998(75)80028-6. PMID: 164695.
  9. Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, Yu X. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188409. doi: 10.1016/j.bbcan.2020.188409. Epub 2020 Aug 19. PMID: 32827580.
  10. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007 Apr;33(3):266-70. doi: 10.1016/j.ejso.2006.10.004. Epub 2006 Nov 9. PMID: 17097848.
  11. Kim J, Bamlet WR, Oberg AL, Chaffee KG, Donahue G, Cao XJ, Chari S, Garcia BA, Petersen GM, Zaret KS. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med. 2017 Jul 12;9(398):eaah5583. doi: 10.1126/scitranslmed.aah5583. PMID: 28701476; PMCID: PMC5727893.
  12. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979 Nov;5(6):957-71. doi: 10.1007/BF01542654. PMID: 94699.
  13. Haridas D, Chakraborty S, Ponnusamy MP, Lakshmanan I, Rachagani S, Cruz E, Kumar S, Das S, Lele SM, Anderson JM, Wittel UA, Hollingsworth MA, Batra SK. Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One. 2011;6(10):e26839. doi: 10.1371/journal.pone.0026839. Epub 2011 Oct 31. PMID: 22066010; PMCID: PMC3204976.
  14. Chen Y, Gao SG, Chen JM, Wang GP, Wang ZF, Zhou B, Jin CH, Yang YT, Feng XS. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients. Cell Biochem Biophys. 2015 Apr;71(3):1287-91. doi: 10.1007/s12013-014-0345-2. PMID: 25486903.
  15. Meng Q, Shi S, Liang C, Liang D, Xu W, Ji S, Zhang B, Ni Q, Xu J, Yu X. Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017 Sep 15;10:4591-4598. doi: 10.2147/OTT.S145708. PMID: 28979147; PMCID: PMC5608082.
  16. Luo G, Liu C, Guo M, Cheng H, Lu Y, Jin K, Liu L, Long J, Xu J, Lu R, Ni Q, Yu X. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Ann Surg. 2017 Apr;265(4):800-805. doi: 10.1097/SLA.0000000000001741. PMID: 28267695.
  17. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006 Jun 20;24(18):2897-902. doi: 10.1200/JCO.2005.05.3934. PMID: 16782929; PMCID: PMC3817569.
  18. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012 Jun;3(2):105-19. doi: 10.3978/j.issn.2078-6891.2011.021. PMID: 22811878; PMCID: PMC3397644.
  19. Kiliç M, Göçmen E, Tez M, Ertan T, Keskek M, Koç M. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg. 2006 Aug;49(4):241-4. PMID: 16948881; PMCID: PMC3207573.
  20. Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, Yanaga K. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg. 2007;14(6):539-44. doi: 10.1007/s00534-006-1184-3. Epub 2007 Nov 30. PMID: 18040617.
  21. Wang QH, Ji ZG, Chen ZG, Li HZ, Fan H, Fan XR, Shi BB, Fang Y. Serum CA 19-9 as a good prognostic biomarker in patients with bladder cancer. Int J Surg. 2015 Mar;15:113-6. doi: 10.1016/j.ijsu.2015.01.031. Epub 2015 Jan 31. PMID: 25647541.
  22. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA, Samra JS, Gill AJ, Kench JG, Merrett ND, Das A, Musgrove EA, Sutherland RL, Biankin AV; NSW Pancreatic Cancer Network. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012 Jul;23(7):1713-22. doi: 10.1093/annonc/mdr561. Epub 2012 Jan 11. PMID: 22241899; PMCID: PMC3387824.
  23. Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab T. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer. 2013 Jan 15;119(2):285-92. doi: 10.1002/cncr.27734. Epub 2012 Jul 11. PMID: 22786786; PMCID: PMC4261189.
  24. Dbouk M, Abe T, Koi C, Ando Y, Saba H, Abou Diwan E, MacGregor-Das A, Blackford AL, Mocci E, Beierl K, Dbouk A, He J, Burkhart R, Lennon AM, Sokoll L, Canto MI, Eshleman JR, Goggins M. Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19-9 Reference Ranges. Clin Cancer Res. 2023 Oct 13;29(20):4178-4185. doi: 10.1158/1078-0432.CCR-23-0655. PMID: 37566230; PMCID: PMC10570677.
  25. Ando Y, Dbouk M, Yoshida T, Saba H, Abou Diwan E, Yoshida K, Dbouk A, Blackford AL, Lin MT, Lennon AM, Burkhart RA, He J, Sokoll L, Eshleman JR, Canto MI, Goggins M. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer. J Clin Oncol. 2024 Jun 20;42(18):2196-2206. doi: 10.1200/JCO.23.01573. Epub 2024 Mar 8. PMID: 38457748; PMCID: PMC11191066.
  26. Luo G, Guo M, Jin K, Liu Z, Liu C, Cheng H, Lu Y, Long J, Liu L, Xu J, Ni Q, Yu X. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Pancreatology. 2016 Nov-Dec;16(6):1057-1062. doi: 10.1016/j.pan.2016.09.013. Epub 2016 Sep 23. PMID: 27692554.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership